LINEZOLID-CRYSTAL FORM II

1. (S)-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl) methyl] acetamide, crystal "Form II" with a powder X-ray diffraction spectrum of: d-spacing ( angstrom ) Two-Theta Angle ( degree) Relative Intensity (%) 12.44 7.10 2 9.26 9.56.37 13.88 6 6.22 14.23 24 5.48 16.18 3 5.28...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
1. Verfasser: BERGREN, MICHAEL, S
Format: Patent
Sprache:eng ; rus
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:1. (S)-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl) methyl] acetamide, crystal "Form II" with a powder X-ray diffraction spectrum of: d-spacing ( angstrom ) Two-Theta Angle ( degree) Relative Intensity (%) 12.44 7.10 2 9.26 9.56.37 13.88 6 6.22 14.23 24 5.48 16.18 3 5.28 100 5.01 17.69 2 4.57 19.41 4 4.50 19.69 29.93 6 4.11 21.61 15 3.97 22.39 23 3.89 22.878 23.52 7 3.68 24.16 1 3.52 25.28 13 3.34 3.30 27.01 3 3.21 27.77 1 2. (S)-N-[[3-[3-flu4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide, crystal "Form II" with an infrared (IR) spectrum as a mineral oil mull: 3364, 1748, 1675, 1537, 1517, 1445, 1410, 1401, 1358, 1329, 1287, 1274, 1253, 1237, 1221, 1145, 1130, 1123, 1116, 1078, 1066, 1049, 907, 852 and 758 cm . 3. A process to prepare (S)-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide, crystal "Form II" which comprises: (1) producing: (S)-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-xazolidinyl]methyl]acetamide in greater than 98% enantiomeric purity, (2) mixing the greater than 98% enantiomerically pure (S)-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide in a solvent or mixture of solvents at a temperature below a temperature of about 80 degree and (3) separating the (S)-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide crystal "Form II" from the solvent(s). 4. A process according to claim 3 where the enantiomeric purity is greater than 99%. 5. A process according to claim 4 where the enantiomeric purity is greater than 99.5%. 6. A process according to claim 3 where the solvent is selected from the group consisting of compounds of the formula: water, acetonitrile, chloroform, methylene chloride, toluene, R1-OH where R1 is C1-C6 alkyl, R1-CO-R2 where R2 is C1-C6 alkyl or phenyl substituted with 1 thru 3 R1 where R1 is as defined above, and where R1 is as defined above, R1-CO-O-R2 where R1 is C1-C6 alkyl and R1 is as defined above, R1-O-R2 where R1 is C1-C6 alkyl and R1 is as defined above. 7. A process according to claim 6 where the solvent is selected from the group consisting of water, ethyl acetate, methanol, ethanol, propanol, i-propanol, butanol, acetonitrile, acetone, methyl ethyl ketone, chloroform, methylene chloride, toluene, xylene, diethyl ether, or methyl-t-butyl ether. 8. A process according to claim 6 where the solvent is selected from the group consisting of ethyl acetate, acetone, acetonitrile, propanol, or i